New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export AZN’s income statement to Excel — free account
AstraZeneca PLC
AZNHealthcare Drug Manufacturers General
AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024.
- Revenue
- +6.70%
- EPS
- +23.5%
- Free cash flow
- +1.99%
- Total debt
- +1.75%
Quarter to September 2026, against a year earlier
175.75
0.30
+0.17%
Follow AZN
Alert me
Analysts’ price targets Wall Street, collected weekly
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 23,002 | 22,465 | 22,090 | 24,384 | 26,617 | 37,417 | 44,351 | 45,811 | 54,073 | 58,739 | 62,384 | +11.0% | 63,376 | 67,393 | 71,464 | +6.8% | |
| Gross margin, % | 82.06 | 80.78 | 77.66 | 79.82 | 80.09 | 66.76 | 72.06 | 81.95 | 81.12 | 81.90 | 81.94 | (0.2) pt | ||||||
| EBT | 3,552 | 2,227 | 1,993 | 1,548 | 3,916 | (265) | 2,501 | 6,899 | 8,691 | 12,402 | 13,300 | +14.9% | ||||||
| EBT margin, % | 15.44 | 9.91 | 9.02 | 6.35 | 14.71 | (0.71) | 5.64 | 15.06 | 16.07 | 21.11 | 21.32 | +5.7 pt | ||||||
| Net income | 3,552 | 2,227 | 1,993 | 1,548 | 3,916 | (265) | 2,501 | 6,899 | 8,691 | 12,402 | 13,300 | +14.9% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 18.18 | 17.74 | 17.43 | 18.74 | 20.29 | 26.39 | 28.65 | 29.57 | 34.89 | 37.90 | 40.22 | +8.5% | |||||
| Earnings | 2.76 | 2.38 | 1.70 | 1.02 | 2.44 | 0.08 | 2.12 | 3.84 | 4.54 | 6.60 | 7.12 | +10.2% | ||||||
| Cash flow | 3.28 | 2.83 | 2.07 | 2.28 | 3.66 | 4.21 | 6.34 | 6.68 | 7.65 | 9.40 | 8.53 | +12.4% | ||||||
| Capex | (0.64) | (0.13) | 0.77 | (0.27) | (1.18) | (1.13) | (1.19) | (2.17) | (2.84) | (3.71) | (4.45) | +21.7% | ||||||
| Free cash flow | 2.64 | 2.70 | 2.84 | 2.02 | 2.48 | 3.08 | 5.15 | 4.51 | 4.81 | 5.69 | 4.08 | +8.9% | ||||||
| Book value | 13.18 | 13.15 | 11.08 | 11.22 | 11.92 | 27.71 | 23.94 | 25.28 | 26.37 | 31.43 | 33.41 | +10.1% | ||||||
| Shares, m | 1,265 | 1,266 | 1,267 | 1,301 | 1,312 | 1,418 | 1,548 | 1,549 | 1,550 | 1,550 | 1,550 | +2.3% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 19.94 | 28.82 | 44.68 | 95.28 | 41.06 | 386.17 | 63.76 | 34.41 | 28.59 | 26.58 | 24.64 | 76.9 | |||||
| P/S | 3.05 | 3.87 | 4.36 | 5.39 | 4.98 | 4.39 | 4.76 | 4.49 | 3.73 | 4.63 | 4.36 | 4.4 | ||||||
| P/B | 4.21 | 5.22 | 6.85 | 9.00 | 8.47 | 4.18 | 5.70 | 5.25 | 4.93 | 5.58 | 5.25 | 5.9 | ||||||
| EV/Sales | 3.52 | 4.45 | 4.95 | 5.85 | 5.41 | 5.01 | 5.25 | 4.96 | 4.16 | 5.00 | 4.73 | 4.9 | ||||||
| EV/FCF | 24.25 | 29.28 | 30.42 | 54.42 | 44.33 | 43.00 | 29.25 | 32.49 | 30.16 | 33.32 | 46.64 | 35.1 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | 4,145 | 3,578 | 2,618 | 2,969 | 4,799 | 5,963 | 9,808 | 10,345 | 11,861 | 14,575 | 13,232 | +15.0% | |||||
| Capex | (805) | (161) | 979 | (347) | (1,549) | (1,600) | (1,842) | (3,355) | (4,408) | (5,756) | (6,899) | +24.4% | ||||||
| Free cash flow | 3,340 | 3,417 | 3,597 | 2,622 | 3,250 | 4,363 | 7,966 | 6,990 | 7,453 | 8,819 | 6,333 | +11.4% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | (1,994) | (3,233) | (701) | (2,554) | (763) | 3,650 | (3,700) | (5,488) | (2,039) | (1,894) | 181 | n/m | |||||
| Net debt | 10,879 | 13,225 | 13,175 | 11,298 | 11,565 | 23,313 | 21,787 | 21,416 | 23,135 | 21,988 | 23,228 | +8.1% | ||||||
| Shareholders’ equity | 16,669 | 16,642 | 14,044 | 14,596 | 15,638 | 39,287 | 37,058 | 39,166 | 40,871 | 48,719 | 51,814 | +12.7% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | 5.71 | 4.77 | 3.48 | 2.19 | 4.99 | 0.13 | 3.26 | 6.03 | 6.86 | 9.38 | 9.41 | +3.7 pt | |||||
| ROIC | 11.12 | 7.69 | 7.78 | 7.06 | 11.86 | 1.05 | 3.99 | 8.45 | 9.77 | 12.15 | 12.31 | +1.0 pt | ||||||
| ROE | 19.89 | 18.02 | 14.05 | 9.32 | 21.14 | 0.41 | 8.61 | 15.63 | 17.58 | 22.83 | 22.56 | +2.9 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 59,700 | 61,100 | 64,400 | 70,600 | 76,100 | 83,100 | 83,500 | 89,900 | 94,300 | 96,100 | — | +5.4% | |||||
| Revenue/emp, $m | 0.39 | 0.37 | 0.34 | 0.35 | 0.35 | 0.45 | 0.53 | 0.51 | 0.57 | 0.61 | — | +5.3% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated Nov 18, 2026
AstraZeneca PLC vs peers in Drug Manufacturers General (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ABBV AbbVie Inc. | $501.2B | 48.8× | 37.6× FY26e | +10.32% (above 0%: growing) | +2,270.00% (above 0%: growing) | +9.97% (above 0%: growing) | 75.38% | 36.01% | Compare |
| MRK Merck & Co., Inc. | $328.6B | 137× | 105× FY26e | +4.68% (above 0%: growing) | −12.07% (below 0%: shrinking) | −19.27% (below 0%: shrinking) | 72.95% | 31.90% | Compare |
| NVS Novartis AG | $277.7B | 28.8× | 24.0× FY26e | +4.67% (above 0%: growing) | −68.81% (below 0%: shrinking) | −17.81% (below 0%: shrinking) | 75.99% | 12.26% | Compare |
| AZN AstraZeneca PLC | $272.1B | 24.6× | 24.2× FY26e | +6.70% (above 0%: growing) | +23.46% (above 0%: growing) | +1.99% (above 0%: growing) | 81.82% | 27.07% | |
| AMGN Amgen Inc. | $237.4B | 25.2× | 24.0× FY26e | +8.45% (above 0%: growing) | +19.39% (above 0%: growing) | −13.98% (below 0%: shrinking) | 73.10% | 35.79% | Compare |
| GILD Gilead Sciences, Inc. | $207.8B | — (loss-making) | — (loss-making) | +6.83% (above 0%: growing) | −20.16% (below 0%: shrinking) | +21.13% (above 0%: growing) | 81.07% | 41.71% | Compare |
| PFE Pfizer Inc. | $158.2B | 38.8× | 18.7× FY26e | −0.43% (below 0%: shrinking) | −9.68% (below 0%: shrinking) | +20.02% (above 0%: growing) | 75.71% | 22.14% | Compare |
| NVO Novo Nordisk A/S | $128.6B | 9.8× | — | +3.87% (above 0%: growing) | −17.14% (below 0%: shrinking) | −14.75% (below 0%: shrinking) | 76.97% | 29.06% | Compare |
| BMY Bristol Myers Squibb Company | $119.3B | 12.9× | 12.0× FY26e | +6.93% (above 0%: growing) | −2.78% (below 0%: shrinking) | −35.95% (below 0%: shrinking) | 68.28% | 19.40% | Compare |
| Median of peers | $222.6B | 28.8× | 24.0× | +5.76% | −10.87% | −14.36% | 75.55% | 30.48% |
AstraZeneca PLC (AZN) Latest News
What happened
- Product AstraZeneca won US and EU approval for Klygefa, a once-weekly self-administered treatment for adults with generalized myasthenia gravis.
- Product AstraZeneca received US approval for perioperative IMFINZI with neoadjuvant enfortumab vedotin for certain adults with muscle-invasive bladder cancer.
- Other AstraZeneca cut about 600 US commercial roles as part of a three-year restructuring targeting $1.5 billion in annual pretax savings and up to $2 billion in charges.
- Deal AstraZeneca acquired Omniose for an undisclosed sum, adding its bioconjugation platform to the company’s infectious disease unit.
- Results AstraZeneca reaffirmed its 2026 earnings guidance and reported third-quarter and nine-month results.
- FDA Grants Priority Tag to AZN's BLA Filing for Gastric Cancer Drug Zacks
- Sonesitatug vedotin granted Priority Review in the US for 2nd and later-line treatment of patients with CLDN18.2-positive advanced gastric/GEJ cancers Business Wire
- Rhythm Pharmaceuticals stock surges 28% on AstraZeneca bid report Investing.com
- AstraZeneca results reassure on long-term growth as three brokers raise price targets Proactive Investors
- AstraZeneca: 3 Key Takeaways for Long-Term Investors The Motley Fool
- AstraZeneca (AZN) Q3 2026 Earnings Call Transcript The Motley Fool transcript
- AstraZeneca (LSE:AZN) Stock Trades At A Discount To Cash Flow Value Simply Wall St.
- AstraZeneca offers compelling risk-reward into 2027 pipeline readouts, says JPMorgan Proactive Investors
- Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer Business Wire
- AstraZeneca Highlights Breakthrough Cancer Data at ESMO 2026 Investor Update MarketBeat
18 more headlines
- AstraZeneca Stock Up 12% in a Month: Time to Buy, Sell or Hold? Zacks
- COVID Vaccine Giant AstraZeneca Stock Jumps 7%. What's Behind It? beincrypto.com
- AstraZeneca Q3 Earnings Call Highlights MarketBeat transcript
- Learn Why The Bull Case For AstraZeneca Stock Could Change Following Earnings Beat Simply Wall St.
- Drugs giant AstraZeneca reveals higher profits, savings plan AFP
- AZN Q3 Earnings Beat Estimates, Oncology Drugs Drive Sales Growth Zacks
- AstraZeneca profit jumps 23% on cancer drugs as it unveils major savings plan Euronews
- AstraZeneca profit jumps 23% on cancer drugs as it unveils major savings plan euronews.com
- AstraZeneca CEO Sees Over $20B Potential From 2027 Drug Trial Readouts – AZN Stock Eyes Breakout After Q3 Earnings Beat Stocktwits
- AstraZeneca results: 9M and Q3 2026 Business Wire
- Drugs giant AstraZeneca reveals higher profits, savings plan AFP
- AstraZeneca Q3 revenue up 7% as cancer drugs offset Farxiga drop Investing.com
- AstraZeneca holds guidance as cancer drugs outrun the Farxiga generics hit Proactive Investors
- AI CRM Adoption Could Be A Key Catalyst For Veeva Systems Stock (VEEV) Simply Wall St.
- AstraZeneca and Mark-Paul Gosselaar Launch Meet Your Mark to Raise Awareness of Cancer Biomarker Testing
- AstraZeneca may start work on cancer vaccines, CEO says Investing.com
- Tremont AI Announces New Research Collaboration to Develop AI Models for Preclinical Safety Assessment Business Wire
- Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027 Business Wire
AZN metrics, ten years each
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score